Loading clinical trials...
Loading clinical trials...
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above
Conditions
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5421
Quadrivalent Influenza mRNA Vaccine MRT5424
+4 more
Locations
20
United States
Long Beach Clinical Trials Site Number : 8400013
Long Beach, California, United States
California Research Foundation Site Number : 8400038
San Diego, California, United States
Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400001
DeLand, Florida, United States
SIMEDHealth, LLC- Site Number : 8400011
Gainesville, Florida, United States
Indago Research and Health Center- Site Number : 8400032
Hialeah, Florida, United States
Cenexel Research Centers of America- Site Number : 8400037
Hollywood, Florida, United States
Start Date
April 1, 2024
Primary Completion Date
June 9, 2025
Completion Date
June 9, 2025
Last Updated
June 19, 2025
NCT06907511
NCT05426174
NCT04024228
NCT05624606
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions